Related Experiment Video
Updated: May 22, 2025
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized
Pam R Taub1, Alexis Gutierrez2, Donavon Wewers3
1Division of Cardiovascular Medicine, University of California, San Diego, California, USA.
Insights
Inclisiran monotherapy significantly reduces low-density lipoprotein cholesterol (LDL-C) compared to placebo and ezetimibe in patients not on lipid-lowering therapy. This study confirms inclisiran
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Trials
Background:
- Inclisiran effectively lowers LDL-C in patients with established atherosclerotic cardiovascular disease (ASCVD) or high genetic risk when used with statins.
- The efficacy of inclisiran as monotherapy in primary prevention populations remained to be determined.
Purpose of the Study:
- To evaluate inclisiran's superiority over placebo and ezetimibe in reducing LDL-C in a primary prevention population without ASCVD.
- To assess inclisiran's safety profile as monotherapy in this cohort.
Main Methods:
- The VICTORION-Mono trial was a 6-month, randomized, double-blind, placebo- and active-controlled phase 3 study.
- Adults (18-75 years) without prior ASCVD, diabetes, or familial hypercholesterolemia, with LDL-C 100-190 mg/dL and low ASCVD risk, were randomized to inclisiran, ezetimibe, or placebo.
- The primary endpoint was the percentage change in LDL-C from baseline to day 150.
Main Results:
- Inclisiran demonstrated a -46.5% change in LDL-C at day 150, significantly greater than placebo (1.4%) and ezetimibe (-11.2%) (P < 0.0001).
- Differences were -47.9% vs placebo and -35.4% vs ezetimibe.
- Inclisiran also improved other lipid profiles and was well tolerated with no new safety concerns.
Conclusions:
- Inclisiran monotherapy is superior to both placebo and ezetimibe in reducing LDL-C in patients not receiving lipid-lowering therapy.
- These findings support inclisiran's efficacy in primary prevention, consistent with its use in statin-treated patients.
- The VICTORION-Mono trial provides novel evidence for inclisiran's role in managing hypercholesterolemia.
Background:
Inclisiran administration twice-yearly (after initial and 3-month doses) effectively reduces low-density lipoprotein cholesterol (LDL-C) in patients on maximally tolerated statins with atherosclerotic cardiovascular disease (ASCVD), risk equivalents, or heterozygous familial hypercholesterolemia.
Objectives:
In this study, the authors sought to evaluate whether inclisiran is superior as monotherapy over placebo and ezetimibe in reducing LDL-C in a primary prevention population without ASCVD.
Methods:
VICTORION-Mono (V-Mono), a 6-month, randomized, double-blind, multicenter, placebo- and active-comparator controlled phase 3 trial, assessed inclisiran monotherapy in adult participants (aged 18-75 years) without prior ASCVD, diabetes, or familial hypercholesterolemia, with a fasting LDL-C of 100-190 mg/dL and 10-year predicted ASCVD risk of <7.5% according to pooled cohort equation, who were not receiving any lipid-lowering therapy. Participants were randomized (2:1:1) to inclisiran, ezetimibe, or placebo. The primary endpoint was percentage change in LDL-C from baseline, and key secondary endpoints included absolute change in LDL-C and percentage change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to day 150. The study did not evaluate twice-yearly inclisiran dosing beyond the first 180 days. Safety was also assessed.
Results:
Overall, 350 participants were randomized (n = 174, 89, and 87 to inclisiran, ezetimibe, or placebo, respectively) and received the assigned treatments. The study included a diverse population: 62.6% of participants were female, 10.6% were Black or African American, and 39.7% were Hispanic/Latino. Mean participant age was 46.1 years, mean baseline LDL-C level was 135.4 mg/dL, mean body mass index was 29.8 kg/m2, and median 10-year predicted ASCVD risk score was 2.2%. The mean percentage change in LDL-C from baseline at day 150 for placebo was 1.4%, for ezetimibe -11.2%, and inclisiran -46.5%. The difference in the change from baseline with inclisiran vs placebo was -47.9% and vs ezetimibe was -35.4% (both P < 0.0001). Inclisiran treatment also demonstrated favorable improvements in other lipid and lipoprotein(a) levels. Inclisiran was well tolerated, with no new safety concerns.
Conclusions:
V-Mono demonstrates for the first time that in patients not receiving lipid-lowering therapy, inclisiran as monotherapy, is superior to both placebo and ezetimibe in reducing LDL-C levels over a 6-month follow-up period and was well tolerated. These findings are consistent with previous observations in statin-treated patients. (Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy [VICTORION-Mono]; NCT05763875).
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:23Dipeptidyl Peptidase 4 Inhibitors
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:13Therapeutic Index